Skip to main content
Premium Trial:

Request an Annual Quote

Seqster Closes $12M Series A Funding Round

NEW YORK – Seqster said Thursday that it has completed a $12 million Series A round of venture capital financing.

OmniHealth Holdings led the investment round, with participation from Takeda Digital Ventures and Anne Wojcicki, founder and CEO of 23andMe.

San Diego-based Seqster collects individuals' health data from wearables, consumer genetic testing, electronic health records, and social determinants of health, giving users the ability to explore it on their own or share it with others. Customers can also contribute specific health data to research, and caregivers can use the platform to manage their loved ones' medical data in a single portal.

The firm said that it will use the funding for technology development and overall growth.

"The company is making significant inroads in the healthcare space, where access to complete longitudinal patient data will lower costs and improve patient outcomes. This new investment will enable the company to expand further into healthcare, where Seqster's software has numerous applications," Tim O'Donnell, managing partner of OmniHealth Holdings, said in a statement.

O'Donnell said that Seqster adds "significant value" to pharmaceutical companies in terms of recruitment and tracking of clinical trial participants.

"Seqster was built on the foundation that real-time access to a patient's complete medical history can solve major pain points across the healthcare continuum, impacting lives at scale," added Ardy Arianpour, CEO and cofounder of Seqster. "We are excited to have investors who are experienced operators and who share our mission and vision to change the way an enterprise or a patient can capture, refine, and manage a multitude of disparate data sources in real time, and present that aggregate in a way that solves real healthcare challenges."

Just last month, the firm announced a partnership with drug development data aggregation startup Medable to integrate real-world genomic and phenotypic data for decentralized clinical trials.